TipRanks
Biora Therapeutics (BIORQ)
OTHER OTC:BIORQ
US Market
Want to see BIORQ full AI Analyst Report?

Biora Therapeutics (BIORQ) Ratios

1,085 Followers

Biora Therapeutics Ratios

BIORQ's free cash flow for Q3 2024 was $1.00. For the 2024 fiscal year, BIORQ's free cash flow was decreased by $ and operating cash flow was $-632.69. See a summary of the company’s cash flow.
Ratios
TTM
Dec 23Dec 22Dec 21Dec 20
Liquidity Ratios
Current Ratio
0.30 ― ― ― ―
Quick Ratio
0.30 ― ― ― ―
Cash Ratio
0.24 ― ― ― ―
Solvency Ratio
-0.93 ― ― ― ―
Operating Cash Flow Ratio
-0.77 ― ― ― ―
Short-Term Operating Cash Flow Coverage
-24.54 ― ― ― ―
Net Current Asset Value
$ -113.56M$ ―$ ―$ ―$ ―
Leverage Ratios
Debt-to-Assets Ratio
1.52 ― ― ― ―
Debt-to-Equity Ratio
-0.47 ― ― ― ―
Debt-to-Capital Ratio
-0.88 ― ― ― ―
Long-Term Debt-to-Capital Ratio
-0.76 ― ― ― ―
Financial Leverage Ratio
-0.31 ― ― ― ―
Debt Service Coverage Ratio
-9.67 ― ― ― ―
Interest Coverage Ratio
-6.84 ― ― ― ―
Debt to Market Cap
101.13K ― ― ― ―
Interest Debt Per Share
36.29 ― ― ― ―
Net Debt to EBITDA
-0.28 ― ― ― ―
Profitability Margins
Gross Profit Margin
100.00%――――
EBIT Margin
-2865225.00%――――
EBITDA Margin
-2851350.00%――――
Operating Profit Margin
-1678575.00%――――
Pretax Profit Margin
-3110600.00%――――
Net Profit Margin
-3102875.00%――――
Continuous Operations Profit Margin
-3108350.00%――――
Net Income Per EBT
99.75%――――
EBT Per EBIT
185.31%――――
Return on Assets (ROA)
-397.61%――――
Return on Equity (ROE)
121.86%――――
Return on Capital Employed (ROCE)
211.43%――――
Return on Invested Capital (ROIC)
232.28%――――
Return on Tangible Assets
-493.64%――――
Earnings Yield
-78686818.03%――――
Efficiency Ratios
Receivables Turnover
<0.01 ― ― ― ―
Payables Turnover
0.00 ― ― ― ―
Inventory Turnover
0.00 ― ― ― ―
Fixed Asset Turnover
<0.01 ― ― ― ―
Asset Turnover
<0.01 ― ― ― ―
Working Capital Turnover Ratio
>-0.01 ― ― ― ―
Cash Conversion Cycle
75.74K ― ― ― ―
Days of Sales Outstanding
75.74K ― ― ― ―
Days of Inventory Outstanding
0.00 ― ― ― ―
Days of Payables Outstanding
0.00 ― ― ― ―
Operating Cycle
75.74K ― ― ― ―
Cash Flow Ratios
Operating Cash Flow Per Share
-30.75 ― ― ― ―
Free Cash Flow Per Share
-30.81 ― ― ― ―
CapEx Per Share
0.07 ― ― ― ―
Free Cash Flow to Operating Cash Flow
1.00 ― ― ― ―
Dividend Paid and CapEx Coverage Ratio
-470.86 ― ― ― ―
Capital Expenditure Coverage Ratio
-470.86 ― ― ― ―
Operating Cash Flow Coverage Ratio
-1.02 ― ― ― ―
Operating Cash Flow to Sales Ratio
-12.12K ― ― ― ―
Free Cash Flow Yield
-10752654.87%――――
Valuation Ratios
Price-to-Earnings (P/E) Ratio
>-0.01 ― ― ― ―
Price-to-Sales (P/S) Ratio
0.11 ― ― ― ―
Price-to-Book (P/B) Ratio
>-0.01 ― ― ― ―
Price-to-Free Cash Flow (P/FCF) Ratio
>-0.01 ― ― ― ―
Price-to-Operating Cash Flow Ratio
>-0.01 ― ― ― ―
Price-to-Earnings Growth (PEG) Ratio
>-0.01 ― ― ― ―
Price-to-Fair Value
>-0.01 ― ― ― ―
Enterprise Value Multiple
-0.28 ― ― ― ―
Enterprise Value
32.22M ― ― ― ―
EV to EBITDA
-0.28 ― ― ― ―
EV to Sales
8.05K ― ― ― ―
EV to Free Cash Flow
-0.66 ― ― ― ―
EV to Operating Cash Flow
-0.66 ― ― ― ―
Tangible Book Value Per Share
-68.15 ― ― ― ―
Shareholders’ Equity Per Share
-64.30 ― ― ― ―
Tax and Other Ratios
Effective Tax Rate
<0.01 ― ― ― ―
Revenue Per Share
<0.01 ― ― ― ―
Net Income Per Share
-78.69 ― ― ― ―
Tax Burden
1.00 ― ― ― ―
Interest Burden
1.09 ― ― ― ―
Research & Development to Revenue
7.46K ― ― ― ―
SG&A to Revenue
9.33K ― ― ― ―
Stock-Based Compensation to Revenue
4.12K ― ― ― ―
Income Quality
0.39 ― ― ― ―
Currency in USD